Tafasitamab (MOR208, XmAb5574) is a humanized Fc-engineered anti CD19 mAb that its preclinical activity has been shown in patients with R/R NHL including MCL, FL, and DLBCL (23). Here, CD19 is linked to mantle cell lymphoma.